What is the appropriate dosing regimen of artesunate‑lumefantrine in patients with chronic kidney disease, and are any dose adjustments required?

Artemether-Lumefantrine Dosing in Chronic Kidney Disease

No dose adjustment is required for artemether-lumefantrine in patients with chronic kidney disease, including those on hemodialysis. 1

Dosing Regimen

The standard dosing regimen for artemether-lumefantrine remains unchanged regardless of renal function:

• Adults ≥35 kg: 4 tablets per dose (80 mg artemether/480 mg lumefantrine)
• Dosing schedule: 6 doses over 3 days
  • Initial dose at time 0
  • Second dose at 8 hours
  • Then twice daily (morning and evening) for the following 2 days 2, 1

Critical administration requirement: Must be taken with food to ensure adequate absorption 2, 1

Evidence Supporting No Dose Adjustment

Pharmacokinetic Rationale

The FDA label explicitly states that no dose adjustment is advised for patients with renal impairment based on pharmacokinetic data from 16 healthy subjects demonstrating no or insignificant renal excretion of lumefantrine, artemether, or its active metabolite dihydroartemisinin (DHA) 1. Both artemether and lumefantrine are primarily metabolized hepatically via CYP3A4, not renally eliminated 1.

Clinical Experience

A case report successfully documented treatment of Plasmodium malariae malaria with standard-dose artemether-lumefantrine in a patient with end-stage kidney disease on hemodialysis 3. The patient achieved parasitological cure without dose modification, supporting the safety and efficacy of standard dosing in severe renal impairment.

Important Caveats

Hepatic Impairment

While no adjustment is needed for renal dysfunction, no dosage adjustment is necessary only for mild-to-moderate hepatic impairment. The drug has not been studied in severe hepatic impairment 1.

Dialysis Considerations

Artemether-lumefantrine is unlikely to be removed during hemodialysis due to the drugs' pharmacokinetic properties (high lipophilicity and protein binding) 3. No supplemental dosing post-dialysis is required.

Monitoring in CKD

Standard monitoring applies:

• Parasitemia assessment at day 3 (expect 75% reduction) and day 7 (expect negative result) 2
• ECG monitoring if QT prolongation risk factors present (common in CKD patients with electrolyte abnormalities) 1
• Monitor for hypokalemia and hypomagnesemia, which increase QT prolongation risk 1

Clinical Pitfalls to Avoid

1. Food requirement: The most common error is administering without food. In CKD patients who may have poor appetite or nausea, ensure administration with at least 1-2 teaspoons of fat-containing food or drink 2, 1

2. Drug interactions: CKD patients often take multiple medications. Avoid coadministration with strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's wort) as this is contraindicated and reduces antimalarial efficacy 1

3. QT prolongation: CKD patients frequently have electrolyte disturbances. Correct hypokalemia and hypomagnesemia before treatment and avoid other QT-prolonging drugs 1

4. Polypharmacy: While polypharmacy is highly prevalent in CKD patients (91% in one study), artemether-lumefantrine's lack of renal elimination makes it a safer choice than renally-cleared alternatives 4